Tim Wilsdon is speaking during the conference in a session titled “Improving Patient Access to Innovative Cancer Therapies: The Role of Managed Entry Agreements.”
For more information on this event, click here.
The impact of price controls on rare disease medicines access and lessons for the US
US policy has long recognized this challenge, beginning with the Orphan Drug Act of 1983 and continuing with recent exemptions for certain orphan indications...